Stephen O'rahilly

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8234065/publications.pdf

Version: 2024-02-01

466 73,064 134 papers citations h-index

256 g-index

495 all docs

495
docs citations

495 times ranked 59592 citing authors

#	Article	IF	Citations
1	Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature, 1997, 387, 903-908.	13.7	2,664
2	Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nature Genetics, 2010, 42, 937-948.	9.4	2,634
3	TheGPR54Gene as a Regulator of Puberty. New England Journal of Medicine, 2003, 349, 1614-1627.	13.9	2,297
4	Effects of Recombinant Leptin Therapy in a Child with Congenital Leptin Deficiency. New England Journal of Medicine, 1999, 341, 879-884.	13.9	1,760
5	Six new loci associated with body mass index highlight a neuronal influence on body weight regulation. Nature Genetics, 2009, 41, 25-34.	9.4	1,572
6	Clinical Spectrum of Obesity and Mutations in the Melanocortin 4 Receptor Gene. New England Journal of Medicine, 2003, 348, 1085-1095.	13.9	1,475
7	The Obesity-Associated <i>FTO</i> Gene Encodes a 2-Oxoglutarate-Dependent Nucleic Acid Demethylase. Science, 2007, 318, 1469-1472.	6.0	1,305
8	Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus and hypertension. Nature, 1999, 402, 880-883.	13.7	1,286
9	Common variants near MC4R are associated with fat mass, weight and risk of obesity. Nature Genetics, 2008, 40, 768-775.	9.4	1,179
10	Obesity and impaired prohormone processing associated with mutations in the human prohormone convertase 1 gene. Nature Genetics, 1997, 16, 303-306.	9.4	1,068
11	A frameshift mutation in MC4R associated with dominantly inherited human obesity. Nature Genetics, 1998, 20, 111-112.	9.4	1,026
12	The UK10K project identifies rare variants in health and disease. Nature, 2015, 526, 82-90.	13.7	1,014
13	Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. Journal of Clinical Investigation, 2002, 110, 1093-1103.	3.9	953
14	The genetic architecture of type 2 diabetes. Nature, 2016, 536, 41-47.	13.7	952
15	International Union of Pharmacology. LXI. Peroxisome Proliferator-Activated Receptors. Pharmacological Reviews, 2006, 58, 726-741.	7.1	869
16	TAC3 and TACR3 mutations in familial hypogonadotropic hypogonadism reveal a key role for Neurokinin B in the central control of reproduction. Nature Genetics, 2009, 41, 354-358.	9.4	817
17	A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance. Nature Genetics, 2012, 44, 659-669.	9.4	762
18	PPARÂ and human metabolic disease. Journal of Clinical Investigation, 2006, 116, 581-589.	3.9	717

#	Article	IF	CITATIONS
19	Resistin / Fizz3 Expression in Relation to Obesity and Peroxisome Proliferator-Activated Receptor-Â Action in Humans. Diabetes, 2001, 50, 2199-2202.	0.3	716
20	Mapping cis- and trans-regulatory effects across multiple tissues in twins. Nature Genetics, 2012, 44, 1084-1089.	9.4	701
21	Dominant and recessive inheritance of morbid obesity associated with melanocortin 4 receptor deficiency. Journal of Clinical Investigation, 2000, 106, 271-279.	3.9	696
22	Genetics of body-weight regulation. Nature, 2000, 404, 644-651.	13.7	682
23	Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. Journal of Clinical Investigation, 2002, 110, 1093-1103.	3.9	670
24	LMNA, encoding lamin A/C, is mutated in partial lipodystrophy. Nature Genetics, 2000, 24, 153-156.	9.4	653
25	The perils of portliness: causes and consequences of visceral adiposity. Diabetes, 2000, 49, 883-888.	0.3	643
26	Clinical and Molecular Genetic Spectrum of Congenital Deficiency of the Leptin Receptor. New England Journal of Medicine, 2007, 356, 237-247.	13.9	610
27	Leptin Regulates Striatal Regions and Human Eating Behavior. Science, 2007, 317, 1355-1355.	6.0	541
28	Induction of Adipocyte Complement-Related Protein of 30 Kilodaltons by PPARÎ ³ Agonists: A Potential Mechanism of Insulin Sensitization. Endocrinology, 2002, 143, 998-1007.	1.4	533
29	Impaired Pulsatile Secretion of Insulin in Relatives of Patients with Non-Insulin-Dependent Diabetes. New England Journal of Medicine, 1988, 318, 1225-1230.	13.9	525
30	A Family with Severe Insulin Resistance and Diabetes Due to a Mutation in AKT2. Science, 2004, 304, 1325-1328.	6.0	509
31	The Hormonal Control of Food Intake. Cell, 2007, 129, 251-262.	13.5	508
32	A de novo mutation affecting human TrkB associated with severe obesity and developmental delay. Nature Neuroscience, 2004, 7, 1187-1189.	7.1	499
33	Large, rare chromosomal deletions associated with severe early-onset obesity. Nature, 2010, 463, 666-670.	13.7	487
34	A new highly penetrant form of obesity due to deletions on chromosome 16p11.2. Nature, 2010, 463, 671-675.	13.7	476
35	Genetics of Obesity in Humans. Endocrine Reviews, 2006, 27, 710-718.	8.9	452
36	Integrative genomic analysis implicates limited peripheral adipose storage capacity in the pathogenesis of human insulin resistance. Nature Genetics, 2017, 49, 17-26.	9.4	452

#	Article	IF	CITATIONS
37	Obesity Associated Genetic Variation in <i>FTO </i> Is Associated with Diminished Satiety. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 3640-3643.	1.8	443
38	Trophoblast organoids as a model for maternal–fetal interactions during human placentation. Nature, 2018, 564, 263-267.	13.7	436
39	Hyperphagia, Severe Obesity, Impaired Cognitive Function, and Hyperactivity Associated With Functional Loss of One Copy of the Brain-Derived Neurotrophic Factor (BDNF) Gene. Diabetes, 2006, 55, 3366-3371.	0.3	421
40	Human Metabolic Syndrome Resulting From Dominant-Negative Mutations in the Nuclear Receptor Peroxisome Proliferator-Activated Receptor-Â. Diabetes, 2003, 52, 910-917.	0.3	412
41	Modulation of Blood Pressure by Central Melanocortinergic Pathways. New England Journal of Medicine, 2009, 360, 44-52.	13.9	412
42	The Architecture of Gene Regulatory Variation across Multiple Human Tissues: The MuTHER Study. PLoS Genetics, 2011, 7, e1002003.	1.5	392
43	Monogenic Obesity in Humans. Annual Review of Medicine, 2005, 56, 443-458.	5.0	367
44	Further evidence for an association between non-insulin-dependent diabetes mellitus and chronic hepatitis C virus infection. Hepatology, 1999, 30, 1059-1063.	3.6	358
45	Evidence for Gene-Nutrient Interaction at the PPARÂ Locus. Diabetes, 2001, 50, 686-689.	0.3	358
46	Influence of Leptin on Arterial Distensibility. Circulation, 2002, 106, 1919-1924.	1.6	357
47	Partial leptin deficiency and human adiposity. Nature, 2001, 414, 34-35.	13.7	356
48	Serum Ghrelin Levels Are Inversely Correlated with Body Mass Index, Age, and Insulin Concentrations in Normal Children and Are Markedly Increased in Prader-Willi Syndrome. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 174-178.	1.8	356
49	A genome-wide association meta-analysis identifies new childhood obesity loci. Nature Genetics, 2012, 44, 526-531.	9.4	352
50	Regulation of Adipose Cell Number in Man. Clinical Science, 1997, 92, 3-11.	1.8	349
51	Associations between body-mass index and COVID-19 severity in 6·9 million people in England: a prospective, community-based, cohort study. Lancet Diabetes and Endocrinology,the, 2021, 9, 350-359.	5 . 5	348
52	Mice lacking pro-opiomelanocortin are sensitive to high-fat feeding but respond normally to the acute anorectic effects of peptide-YY3-36. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 4695-4700.	3.3	345
53	Association of a Homozygous Nonsense Caveolin-1 Mutation with Berardinelli-Seip Congenital Lipodystrophy. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 1129-1134.	1.8	343
54	The central melanocortin system directly controls peripheral lipid metabolism. Journal of Clinical Investigation, 2007, 117, 3475-3488.	3.9	341

#	Article	IF	CITATIONS
55	Loss-of-Function Mutation in the Dioxygenase-Encoding FTO Gene Causes Severe Growth Retardation and Multiple Malformations. American Journal of Human Genetics, 2009, 85, 106-111.	2.6	340
56	Genome-Wide Association Identifies Nine Common Variants Associated With Fasting Proinsulin Levels and Provides New Insights Into the Pathophysiology of Type 2 Diabetes. Diabetes, 2011, 60, 2624-2634.	0.3	335
57	Global Analysis of DNA Methylation Variation in Adipose Tissue from Twins Reveals Links to Disease-Associated Variants in Distal Regulatory Elements. American Journal of Human Genetics, 2013, 93, 876-890.	2.6	330
58	GDF15 mediates the effects of metformin on body weight and energy balance. Nature, 2020, 578, 444-448.	13.7	326
59	Genetic Predisposition to an Impaired Metabolism of the Branched-Chain Amino Acids and Risk of Type 2 Diabetes: A Mendelian Randomisation Analysis. PLoS Medicine, 2016, 13, e1002179.	3.9	324
60	Association Between Low-Density Lipoprotein Cholesterol–Lowering Genetic Variants and Risk of Type 2 Diabetes. JAMA - Journal of the American Medical Association, 2016, 316, 1383.	3.8	310
61	Human genetics illuminates the paths to metabolic disease. Nature, 2009, 462, 307-314.	13.7	304
62	Depletion of stromal cells expressing fibroblast activation protein- $\hat{l}\pm$ from skeletal muscle and bone marrow results in cachexia and anemia. Journal of Experimental Medicine, 2013, 210, 1137-1151.	4.2	304
63	A Genomewide Scan for Loci Predisposing to Type 2 Diabetes in a U.K. Population (The Diabetes UK) Tj ETQq1 1 C Locus on Chromosome 1q. American Journal of Human Genetics, 2001, 69, 553-569.).784314 r 2.6	gBT /Overlo 300
64	Differential Lipid Partitioning Between Adipocytes and Tissue Macrophages Modulates Macrophage Lipotoxicity and M2/M1 Polarization in Obese Mice. Diabetes, 2011, 60, 797-809.	0.3	297
65	Adipogenesis at a glance. Journal of Cell Science, 2011, 124, 2681-2686.	1.2	296
66	Genetic variation near IRS1 associates with reduced adiposity and an impaired metabolic profile. Nature Genetics, 2011, 43, 753-760.	9.4	289
67	Leptin Mediates the Increase in Blood Pressure Associated with Obesity. Cell, 2014, 159, 1404-1416.	13.5	288
68	Activation of Peroxisome Proliferator–Activated Receptor (PPAR)ΠPromotes Reversal of Multiple Metabolic Abnormalities, Reduces Oxidative Stress, and Increases Fatty Acid Oxidation in Moderately Obese Men. Diabetes, 2008, 57, 332-339.	0.3	287
69	GDF15 Provides an Endocrine Signal of Nutritional Stress in Mice and Humans. Cell Metabolism, 2019, 29, 707-718.e8.	7.2	286
70	Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity. Nature Genetics, 2018, 50, 26-41.	9.4	286
71	Pharmacological Inhibition of Glucosylceramide Synthase Enhances Insulin Sensitivity. Diabetes, 2007, 56, 1341-1349.	0.3	280
72	Genome-wide SNP and CNV analysis identifies common and low-frequency variants associated with severe early-onset obesity. Nature Genetics, 2013, 45, 513-517.	9.4	278

#	Article	IF	Citations
73	Small-intestinal dysfunction accompanies the complex endocrinopathy of human proprotein convertase 1 deficiency. Journal of Clinical Investigation, 2003, 112, 1550-1560.	3.9	276
74	Genetic Syndromes of Severe Insulin Resistance. Endocrine Reviews, 2011, 32, 498-514.	8.9	274
75	Tumor Necrosis Factor-α Induces Apoptosis of Human Adipose Cells. Diabetes, 1997, 46, 1939-1944.	0.3	271
76	Correlation of the leptin:adiponectin ratio with measures of insulin resistance in non-diabetic individuals. Diabetologia, 2009, 52, 2345-2349.	2.9	270
77	Mosaic overgrowth with fibroadipose hyperplasia is caused by somatic activating mutations in PIK3CA. Nature Genetics, 2012, 44, 928-933.	9.4	269
78	Set points, settling points and some alternative models: theoretical options to understand how genes and environments combine to regulate body adiposity. DMM Disease Models and Mechanisms, 2011, 4, 733-745.	1.2	266
79	Two Novel Missense Mutations in G Protein-Coupled Receptor 54 in a Patient with Hypogonadotropic Hypogonadism. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 1849-1855.	1.8	264
80	Candidate Gene Association Study in Type 2 Diabetes Indicates a Role for Genes Involved in \hat{I}^2 -Cell Function as Well as Insulin Action. PLoS Biology, 2003, 1, e20.	2.6	262
81	Leptin: a pivotal regulator of human energy homeostasis. American Journal of Clinical Nutrition, 2009, 89, 980S-984S.	2.2	261
82	Postreceptor insulin resistance contributes to human dyslipidemia and hepatic steatosis. Journal of Clinical Investigation, 2009, 119, 315-22.	3.9	256
83	A deletion of the HBII-85 class of small nucleolar RNAs (snoRNAs) is associated with hyperphagia, obesity and hypogonadism. Human Molecular Genetics, 2009, 18, 3257-3265.	1.4	253
84	A missense mutation disrupting a dibasic prohormone processing site in pro-opiomelanocortin (POMC) increases susceptibility to early-onset obesity through a novel molecular mechanism. Human Molecular Genetics, 2002, 11, 1997-2004.	1.4	249
85	Perilipin Deficiency and Autosomal Dominant Partial Lipodystrophy. New England Journal of Medicine, 2011, 364, 740-748.	13.9	248
86	Congenital Leptin Deficiency Due to Homozygosity for the Î"133G Mutation: Report of Another Case and Evaluation of Response to Four Years of Leptin Therapy. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 4821-4826.	1.8	245
87	Serotonin Activates the Hypothalamic-Pituitary-Adrenal Axis via Serotonin 2C Receptor Stimulation. Journal of Neuroscience, 2007, 27, 6956-6964.	1.7	243
88	Genetic Factors in Type 2 Diabetes: The End of the Beginning?. Science, 2005, 307, 370-373.	6.0	239
89	Serotonin 5-HT2C Receptor Agonist Promotes Hypophagia via Downstream Activation of Melanocortin 4 Receptors. Endocrinology, 2008, 149, 1323-1328.	1.4	237
90	Partial lipodystrophy and insulin resistant diabetes in a patient with a homozygous nonsense mutation in <i>CIDEC</i> . EMBO Molecular Medicine, 2009, 1, 280-287.	3.3	235

#	Article	IF	Citations
91	Impaired Processing of Prohormones Associated with Abnormalities of Glucose Homeostasis and Adrenal Function. New England Journal of Medicine, 1995, 333, 1386-1391.	13.9	233
92	Prevalence of Melanocortin-4 Receptor Deficiency in Europeans and Their Age-Dependent Penetrance in Multigenerational Pedigrees. Diabetes, 2008, 57, 2511-2518.	0.3	229
93	Mutations in ligands and receptors of the leptin–melanocortin pathway that lead to obesity. Nature Clinical Practice Endocrinology and Metabolism, 2008, 4, 569-577.	2.9	225
94	Loss of Function of the Melanocortin 2 Receptor Accessory Protein 2 Is Associated with Mammalian Obesity. Science, 2013, 341, 275-278.	6.0	225
95	Acute effects of PYY3–36 on food intake and hypothalamic neuropeptide expression in the mouse. Biochemical and Biophysical Research Communications, 2003, 311, 915-919.	1.0	218
96	20 YEARS OF LEPTIN: Human disorders of leptin action. Journal of Endocrinology, 2014, 223, T63-T70.	1.2	218
97	Phenotypic and Genetic Heterogeneity in Congenital Generalized Lipodystrophy. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 4840-4847.	1.8	217
98	Prospective functional classification of all possible missense variants in PPARG. Nature Genetics, 2016, 48, 1570-1575.	9.4	210
99	A POMC variant implicates \hat{l}^2 -melanocyte-stimulating hormone in the control of human energy balance. Cell Metabolism, 2006, 3, 135-140.	7.2	207
100	Heterozygosity for aPOMC-Null Mutation and Increased Obesity Risk in Humans. Diabetes, 2006, 55, 2549-2553.	0.3	205
101	Mutations in the human melanocortin-4 receptor gene associated with severe familial obesity disrupts receptor function through multiple molecular mechanisms. Human Molecular Genetics, 2003, 12, 561-574.	1.4	201
102	Evaluation of a melanocortin-4 receptor (MC4R) agonist (Setmelanotide) in MC4R deficiency. Molecular Metabolism, 2017, 6, 1321-1329.	3.0	200
103	Proopiomelanocortin and Energy Balance: Insights from Human and Murine Genetics. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 2557-2562.	1.8	197
104	Hyperphagia and Early-Onset Obesity due to a Novel Homozygous Missense Mutation in Prohormone Convertase 1/3. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 3369-3373.	1.8	196
105	Minireview: Human Obesity—Lessons from Monogenic Disorders. Endocrinology, 2003, 144, 3757-3764.	1.4	194
106	Mapping the proteo-genomic convergence of human diseases. Science, 2021, 374, eabj1541.	6.0	192
107	Characterization of the human, mouse and rat PGC1beta (peroxisome-proliferator-activated) Tj ETQq1 1 0.7843	14 rgBT /C	verlock 10 T 185
108	Analysis of parent-offspring trios provides evidence for linkage and association between the insulin gene and type 2 diabetes mediated exclusively through paternally transmitted class III variable number tandem repeat alleles. Diabetes, 2000, 49, 126-130.	0.3	184

#	Article	IF	Citations
109	The Human Lipodystrophy Gene <i>BSCL2/Seipin</i> May Be Essential for Normal Adipocyte Differentiation. Diabetes, 2008, 57, 2055-2060.	0.3	181
110	Expression of the thermogenic nuclear hormone receptor coactivator PGC-1α is reduced in the adipose tissue of morbidly obese subjects. International Journal of Obesity, 2004, 28, 176-179.	1.6	180
111	Lipodystrophy: metabolic insights from a rare disorder. Journal of Endocrinology, 2010, 207, 245-255.	1.2	17 3
112	Low-frequency and rare exome chip variants associate with fasting glucose and type 2 diabetes susceptibility. Nature Communications, 2015, 6, 5897.	5.8	173
113	Studies of Association between the Gene for Calpain-10 and Type 2 Diabetes Mellitus in the United Kingdom. American Journal of Human Genetics, 2001, 69, 544-552.	2.6	171
114	A Gene for Congenital Generalized Lipodystrophy Maps to Human Chromosome 9q34. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 3390-3394.	1.8	167
115	The Metabolic Syndrome: Peroxisome Proliferator-Activated Receptor \hat{l}^3 and Its Therapeutic Modulation. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 2412-2421.	1.8	167
116	Non-DNA binding, dominant-negative, human PPAR \hat{I}^3 mutations cause lipodystrophic insulin resistance. Cell Metabolism, 2006, 4, 303-311.	7.2	164
117	Isomer-Dependent Metabolic Effects of Conjugated Linoleic Acid: Insights From Molecular Markers Sterol Regulatory Element-Binding Protein-1c and LXRÂ. Diabetes, 2002, 51, 2037-2044.	0.3	163
118	An Activating Mutation of <i>AKT2</i> and Human Hypoglycemia. Science, 2011, 334, 474-474.	6.0	162
119	Morbid obesity exposes the association between PNPLA3 I148M (rs738409) and indices of hepatic injury in individuals of European descent. International Journal of Obesity, 2010, 34, 190-194.	1.6	161
120	Trim28 Haploinsufficiency Triggers Bi-stable Epigenetic Obesity. Cell, 2016, 164, 353-364.	13.5	161
121	Human Obesity: A Heritable Neurobehavioral Disorder That Is Highly Sensitive to Environmental Conditions. Diabetes, 2008, 57, 2905-2910.	0.3	160
122	C/EBP transcription factors regulate <i>SREBP1c</i> gene expression during adipogenesis. Biochemical Journal, 2010, 425, 215-224.	1.7	160
123	The Link Between Nutritional Status and Insulin Sensitivity Is Dependent on the Adipocyte-Specific Peroxisome Proliferator-Activated Receptor-Â2 Isoform. Diabetes, 2005, 54, 1706-1716.	0.3	157
124	TCF7L2 Polymorphisms Modulate Proinsulin Levels and Â-Cell Function in a British Europid Population. Diabetes, 2007, 56, 1943-1947.	0.3	154
125	KSR2 Mutations Are Associated with Obesity, Insulin Resistance, and Impaired Cellular Fuel Oxidation. Cell, 2013, 155, 765-777.	13.5	154
126	Association of Genetic Variants Related to Gluteofemoral vs Abdominal Fat Distribution With Type 2 Diabetes, Coronary Disease, and Cardiovascular Risk Factors. JAMA - Journal of the American Medical Association, 2018, 320, 2553.	3.8	152

#	Article	IF	CITATIONS
127	Hypothalamic-Specific Manipulation of Fto, the Ortholog of the Human Obesity Gene FTO, Affects Food Intake in Rats. PLoS ONE, 2010, 5, e8771.	1.1	151
128	An in-frame deletion at the polymerase active site of POLD1 causes a multisystem disorder with lipodystrophy. Nature Genetics, 2013, 45, 947-950.	9.4	151
129	Role for the obesity-related <i>FTO</i> gene in the cellular sensing of amino acids. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 2557-2562.	3.3	150
130	Leptin Predicts a Worsening of the Features of the Metabolic Syndrome Independently of Obesity. Obesity, 2005, 13, 1476-1484.	4.0	148
131	A Genome-Wide Association Study Reveals Variants in ARL15 that Influence Adiponectin Levels. PLoS Genetics, 2009, 5, e1000768.	1.5	148
132	Human SH2B1 mutations are associated with maladaptive behaviors and obesity. Journal of Clinical Investigation, 2012, 122, 4732-4736.	3.9	147
133	Genetic factors in human obesity. Obesity Reviews, 2007, 8, 37-40.	3.1	144
134	Tamoxifen-Induced Anorexia Is Associated With Fatty Acid Synthase Inhibition in the Ventromedial Nucleus of the Hypothalamus and Accumulation of Malonyl-CoA. Diabetes, 2006, 55, 1327-1336.	0.3	143
135	Small-intestinal dysfunction accompanies the complex endocrinopathy of human proprotein convertase 1 deficiency. Journal of Clinical Investigation, 2003, 112, 1550-1560.	3.9	140
136	The Wnt antagonist Dickkopf-1 and its receptors are coordinately regulated during early human adipogenesis. Journal of Cell Science, 2006, 119, 2613-2620.	1,2	138
137	Rare variants in single-minded 1 (SIM1) are associated with severe obesity. Journal of Clinical Investigation, 2013, 123, 3042-3050.	3.9	135
138	Regulation of tumour necrosis factor-alpha release from human adipose tissue in vitro. Journal of Endocrinology, 1999, 163, 33-38.	1,2	134
139	Digenic inheritance of severe insulin resistance in a human pedigree. Nature Genetics, 2002, 31, 379-384.	9.4	134
140	Human Obesity and Type 2 Diabetes Are Associated With Alterations in SREBP1 Isoform Expression That Are Reproduced Ex Vivo by Tumor Necrosis Factor-Â. Diabetes, 2002, 51, 1035-1041.	0.3	133
141	Adult Onset Global Loss of the Fto Gene Alters Body Composition and Metabolism in the Mouse. PLoS Genetics, 2013, 9, e1003166.	1.5	129
142	Heterogeneity of hypothalamic pro-opiomelanocortin-expressing neurons revealed by single-cell RNA sequencing. Molecular Metabolism, 2017, 6, 383-392.	3.0	128
143	WNT10B mutations in human obesity. Diabetologia, 2006, 49, 678-684.	2.9	127
144	Elevated Plasma Adiponectin in Humans with Genetically Defective Insulin Receptors. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 3219-3223.	1.8	127

#	Article	IF	CITATIONS
145	The V103I polymorphism of the MC4R gene and obesity: population based studies and meta-analysis of 29 563 individuals. International Journal of Obesity, 2007, 31, 1437-1441.	1.6	126
146	Mutations disrupting the Kennedy phosphatidylcholine pathway in humans with congenital lipodystrophy and fatty liver disease. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 8901-8906.	3.3	125
147	Monogenic Human Obesity Syndromes. Endocrine Reviews, 2004, 59, 409-424.	7.1	125
148	The energy balance model of obesity: beyond calories in, calories out. American Journal of Clinical Nutrition, 2022, 115, 1243-1254.	2.2	123
149	Detection of Mutations in Insulin-Receptor Gene in NIDDM Patients by Analysis of Single-Stranded Conformation Polymorphisms. Diabetes, 1991, 40, 777-782.	0.3	122
150	Hypogonadotropic Hypogonadism due to a Novel Missense Mutation in the First Extracellular Loop of the Neurokinin B Receptor. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 3633-3639.	1.8	122
151	Obesity due to Melanocortin 4 Receptor (MC4R) Deficiency Is Associated with Increased Linear Growth and Final Height, Fasting Hyperinsulinemia, and Incompletely Suppressed Growth Hormone Secretion. Journal of Clinical Endocrinology and Metabolism, 2011, 96, E181-E188.	1.8	120
152	Insulin-like peptide 5 is an orexigenic gastrointestinal hormone. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 11133-11138.	3. 3	120
153	Genetics of obesity. Philosophical Transactions of the Royal Society B: Biological Sciences, 2006, 361, 1095-1105.	1.8	118
154	A Deletion in the Canine POMC Gene Is Associated with Weight and Appetite in Obesity-Prone Labrador Retriever Dogs. Cell Metabolism, 2016, 23, 893-900.	7.2	117
155	Recent advances: Recent advances in the genetics of severe childhood obesity. Archives of Disease in Childhood, 2000, 83, 31-34.	1.0	113
156	A Quantitative Trait Locus on Chromosome 18q for Physical Activity and Dietary Intake in Hispanic Children. Obesity, 2006, 14, 1596-1604.	1.5	113
157	PCSK1 Mutations and Human Endocrinopathies: From Obesity to Gastrointestinal Disorders. Endocrine Reviews, 2016, 37, 347-371.	8.9	113
158	Cell Proliferation Activities on Skin Fibroblasts from a Short Child with Absence of One Copy of the Type 1 Insulin-Like Growth Factor Receptor (IGF1R) Gene and a Tall Child with Three Copies of the IGF1R Gene. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 5981-5988.	1.8	111
159	GDF15: A Hormone Conveying Somatic Distress to the Brain. Endocrine Reviews, 2020, 41, .	8.9	109
160	Human obesity as a heritable disorder of the central control of energy balance. International Journal of Obesity, 2008, 32, S55-S61.	1.6	106
161	Novel Leptin-Regulated Genes Revealed by Transcriptional Profiling of the Hypothalamic Paraventricular Nucleus. Journal of Neuroscience, 2008, 28, 12419-12426.	1.7	105
162	Meta-analysis of the Gly482Ser variant in PPARGC1A in type 2 diabetes and related phenotypes. Diabetologia, 2006, 49, 501-505.	2.9	102

#	Article	IF	Citations
163	A genomic approach to therapeutic target validation identifies a glucose-lowering <i>GLP1R</i> variant protective for coronary heart disease. Science Translational Medicine, 2016, 8, 341ra76.	5.8	100
164	Rosiglitazone Increases Indexes of Stearoyl-CoA Desaturase Activity in Humans: Link to Insulin Sensitization and the Role of Dominant-Negative Mutation in Peroxisome Proliferator-Activated Receptor-Â. Diabetes, 2005, 54, 1379-1384.	0.3	99
165	Obesity therapy: altering the energy intake-and-expenditure balance sheet. Nature Reviews Drug Discovery, 2002, 1, 276-286.	21.5	98
166	Genetic architecture of human thinness compared to severe obesity. PLoS Genetics, 2019, 15, e1007603.	1.5	98
167	Arachidonic Acid Stimulates Glucose Uptake in 3T3-L1 Adipocytes by Increasing GLUT1 and GLUT4 Levels at the Plasma Membrane. Journal of Biological Chemistry, 2001, 276, 9149-9157.	1.6	94
168	Regional Differences in the Response of Human Pre-Adipocytes to PPARÂ and RXRÂ Agonists. Diabetes, 2002, 51, 718-723.	0.3	94
169	Proteinuric Nephropathy in Acquired and Congenital Generalized Lipodystrophy: Baseline Characteristics and Course during Recombinant Leptin Therapy. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 3199-3207.	1.8	94
170	Prevalence of Loss-of-Function FTO Mutations in Lean and Obese Individuals. Diabetes, 2010, 59, 311-318.	0.3	93
171	Muscle glycogen inharmoniously regulates glycogen synthase activity, glucose uptake, and proximal insulin signaling. American Journal of Physiology - Endocrinology and Metabolism, 2006, 290, E154-E162.	1.8	92
172	Plasma Adiponectin as a Marker of Insulin Receptor Dysfunction. Diabetes Care, 2008, 31, 977-979.	4.3	92
173	Paradoxical Elevation of High-Molecular Weight Adiponectin in Acquired Extreme Insulin Resistance Due to Insulin Receptor Antibodies. Diabetes, 2007, 56, 1712-1717.	0.3	91
174	Hypomorphism in human NSMCE2 linked to primordial dwarfism and insulin resistance. Journal of Clinical Investigation, 2014, 124, 4028-4038.	3.9	90
175	Functional characterization of human NTRK2 mutations identified in patients with severe early-onset obesity. International Journal of Obesity, 2007, 31, 359-364.	1.6	89
176	Effects of the mu-opioid receptor antagonist GSK1521498 on hedonic and consummatory eating behaviour: a proof of mechanism study in binge-eating obese subjects. Molecular Psychiatry, 2013, 18, 1287-1293.	4.1	89
177	A truncation mutation in <i>TBC1D4</i> in a family with acanthosis nigricans and postprandial hyperinsulinemia. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 9350-9355.	3.3	88
178	Transcript and metabolite analysis of the effects of tamoxifen in rat liver reveals inhibition of fatty acid synthesis in the presence of hepatic steatosis. FASEB Journal, 2005, 19, 1108-1119.	0.2	87
179	CNS Leptin Action Modulates Immune Response and Survival in Sepsis. Journal of Neuroscience, 2010, 30, 6036-6047.	1.7	86
180	Human Frame Shift Mutations Affecting the Carboxyl Terminus of Perilipin Increase Lipolysis by Failing to Sequester the Adipose Triglyceride Lipase (ATGL) Coactivator AB-hydrolase-containing 5 (ABHD5). Journal of Biological Chemistry, 2011, 286, 34998-35006.	1.6	85

#	Article	IF	CITATIONS
181	Obesity and FTO: Changing Focus at a Complex Locus. Cell Metabolism, 2014, 20, 710-718.	7.2	84
182	GWAS for BMI: a treasure trove of fundamental insights into the genetic basis of obesity. International Journal of Obesity, 2018, 42, 1524-1531.	1.6	84
183	Does peroxisome proliferator-activated receptor \hat{l}^3 genotype (Pro12ala) modify the association of physical activity and dietary fat with fasting insulin level? Metabolism: Clinical and Experimental, 2004, 53, 11-16.	1.5	83
184	Mitochondrial dysfunction in patients with primary congenital insulin resistance. Journal of Clinical Investigation, 2011, 121, 2457-2461.	3.9	83
185	Potentiation of Glucose Uptake in 3T3-L1 Adipocytes by PPARγ Agonists Is Maintained in Cells Expressing a PPARγ Dominant-Negative Mutant: Evidence for Selectivity in the Downstream Responses to PPARγ Activation. Molecular Endocrinology, 2001, 15, 1729-1738.	3.7	82
186	FTO expression is regulated by availability of essential amino acids. International Journal of Obesity, 2013, 37, 744-747.	1.6	82
187	Hypothalamic loss of Snord116 recapitulates the hyperphagia of Prader-Willi syndrome. Journal of Clinical Investigation, 2018, 128, 960-969.	3.9	81
188	The Effects of Proopiomelanocortin Deficiency on Murine Adrenal Development and Responsiveness to Adrenocorticotropin. Endocrinology, 2004, 145, 4721-4727.	1.4	80
189	Leptin Deficiency Unmasks the Deleterious Effects of Impaired Peroxisome Proliferator-Activated Receptor Function (P465L PPARÂ) in Mice. Diabetes, 2006, 55, 2669-2677.	0.3	80
190	The transcription factors Egr1 and Egr2 have opposing influences on adipocyte differentiation. Cell Death and Differentiation, 2009, 16, 782-789.	5.0	80
191	Human Semaphorin 3 Variants Link Melanocortin Circuit Development and Energy Balance. Cell, 2019, 176, 729-742.e18.	13.5	80
192	Two Naturally Occurring Insulin Receptor Tyrosine Kinase Domain Mutants Provide Evidence That Phosphoinositide 3-Kinase Activation Alone Is Not Sufficient for the Mediation of Insulin's Metabolic and Mitogenic Effects. Journal of Biological Chemistry, 1997, 272, 30208-30214.	1.6	79
193	Insulin resistance as the major cause of impaired glucose tolerance: a self-fulfilling prophesy?. Lancet, The, 1994, 344, 585-589.	6.3	78
194	Leptin Regulates Peripheral Lipid Metabolism Primarily through Central Effects on Food Intake. Endocrinology, 2008, 149, 5432-5439.	1.4	78
195	New advances in the genetics of early onset obesity. International Journal of Obesity, 2005, 29, 1149-1152.	1.6	77
196	Tumor necrosis factor-alpha induces apoptosis of human adipose cells. Diabetes, 1997, 46, 1939-1944.	0.3	77
197	Complement Abnormalities in Acquired Lipodystrophy Revisited. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 10-16.	1.8	76
198	Seipin oligomers can interact directly with AGPAT2 and lipin 1, physically scaffolding critical regulators of adipogenesis. Molecular Metabolism, 2015, 4, 199-209.	3.0	76

#	Article	IF	CITATIONS
199	ETO/MTG8 Is an Inhibitor of C/EBP \hat{l}^2 Activity and a Regulator of Early Adipogenesis. Molecular and Cellular Biology, 2004, 24, 9863-9872.	1.1	75
200	Functional Characterization and Structural Modeling of Obesity Associated Mutations in the Melanocortin 4 Receptor. Endocrinology, 2009, 150, 114-125.	1.4	75
201	The Peroxisome Proliferator-activated Receptor-Î ³ Regulates Murine Pyruvate Carboxylase Gene Expression in Vivo and in Vitro. Journal of Biological Chemistry, 2005, 280, 27466-27476.	1.6	74
202	A Comparative Study of the Central Effects of Specific Proopiomelancortin (POMC)-Derived Melanocortin Peptides on Food Intake and Body Weight in Pomc Null Mice. Endocrinology, 2006, 147, 5940-5947.	1.4	73
203	Mutant insulin receptors in syndromes of insulin resistance. Bailliere's Clinical Endocrinology and Metabolism, 1996, 10, 97-122.	1.0	70
204	Fat: an evolving issue. DMM Disease Models and Mechanisms, 2012, 5, 569-573.	1.2	70
205	Distinct Modulatory Effects of Satiety and Sibutramine on Brain Responses to Food Images in Humans: A Double Dissociation across Hypothalamus, Amygdala, and Ventral Striatum. Journal of Neuroscience, 2010, 30, 14346-14355.	1.7	69
206	The human lipodystrophy protein seipin is an ER membrane adaptor for the adipogenic PA phosphatase lipin 1. Molecular Metabolism, 2013, 2, 38-46.	3.0	69
207	Proopiomelanocortin-Deficient Mice Are Hypersensitive to the Adverse Metabolic Effects of Glucocorticoids. Diabetes, 2005, 54, 2269-2276.	0.3	63
208	The Effects of Neurokinin B upon Gonadotrophin Release in Male Rodents. Journal of Neuroendocrinology, 2010, 22, 181-187.	1.2	63
209	Aldehyde-driven transcriptional stress triggers an anorexic DNA damage response. Nature, 2021, 600, 158-163.	13.7	63
210	Mitochondrial DNA, diabetes and pancreatic pathology in Kearns-Sayre syndrome. Diabetologia, 1995, 38, 868-871.	2.9	62
211	Life without leptin. Nature, 1998, 392, 330-331.	13.7	62
212	Analysis of Genetic Variation in Akt2/PKB-Â in Severe Insulin Resistance, Lipodystrophy, Type 2 Diabetes, and Related Metabolic Phenotypes. Diabetes, 2007, 56, 714-719.	0.3	62
213	Severe obesity and diabetes insipidus in a patient with PCSK1 deficiency. Molecular Genetics and Metabolism, 2013, 110, 191-194.	0.5	62
214	When Two Pandemics Meet: Why Is Obesity Associated with Increased COVID-19 Mortality?. Med, 2020, 1, 33-42.	2.2	62
215	Uncoupling protein 3 genetic variants in human obesity: the c-55t promoter polymorphism is negatively correlated with body mass index in a UK Caucasian population. International Journal of Obesity, 2001, 25, 472-477.	1.6	61
216	Contribution of Variants in the Small Heterodimer Partner Gene to Birthweight, Adiposity, and Insulin Levels: Mutational Analysis and Association Studies in Multiple Populations. Diabetes, 2003, 52, 1288-1291.	0.3	61

#	Article	IF	CITATIONS
217	Genetic Defects in Human Pericentrin Are Associated With Severe Insulin Resistance and Diabetes. Diabetes, 2011, 60, 925-935.	0.3	61
218	Fat mass and obesity-related (FTO) shuttles between the nucleus and cytoplasm. Bioscience Reports, $2014, 34, .$	1.1	61
219	Mutant insulin receptors in syndromes of insulin resistance. Clinical Endocrinology, 1992, 36, 121-132.	1.2	60
220	Loss of Mrap2 is associated with Sim1 deficiency and increased circulating cholesterol. Journal of Endocrinology, 2016, 230, 13-26.	1.2	60
221	Human biallelic MFN2 mutations induce mitochondrial dysfunction, upper body adipose hyperplasia, and suppression of leptin expression. ELife, 2017, 6, .	2.8	60
222	Differences in Signaling Properties of the Cytoplasmic Domains of the Insulin Receptor and Insulin-like Growth Factor Receptor in 3T3-L1 Adipocytes. Journal of Biological Chemistry, 1999, 274, 30864-30873.	1.6	59
223	Microarray Analysis of Insulin and Insulin-like Growth Factor-1 (IGF-1) Receptor Signaling Reveals the Selective Up-regulation of the Mitogen Heparin-binding EGF-like Growth Factor by IGF-1. Journal of Biological Chemistry, 2002, 277, 42480-42487.	1.6	59
224	MC3R links nutritional state to childhood growth and the timing of puberty. Nature, 2021, 599, 436-441.	13.7	59
225	Truncated Human Leptin (î"133) Associated with Extreme Obesity Undergoes Proteasomal Degradation after Defective Intracellular Transport*. Endocrinology, 1999, 140, 1718-1723.	1.4	58
226	Decreased Brown Adipocyte Recruitment and Thermogenic Capacity in Mice with Impaired Peroxisome Proliferator-Activated Receptor (P465L PPARγ) Function. Endocrinology, 2006, 147, 5708-5714.	1.4	57
227	Clinical and Molecular Characterization of a Novel PLIN1 Frameshift Mutation Identified in Patients With Familial Partial Lipodystrophy. Diabetes, 2015, 64, 299-310.	0.3	57
228	Obesity-associated gene <i>TMEM18</i> has a role in the central control of appetite and body weight regulation. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 9421-9426.	3.3	57
229	Tyrosine Agonists Reverse the Molecular Defects Associated with Dominant-Negative Mutations in Human Peroxisome Proliferator-Activated Receptor \hat{l}^3 . Endocrinology, 2004, 145, 1527-1538.	1.4	55
230	Genetic Variants in Human Sterol Regulatory Element Binding Protein-1c in Syndromes of Severe Insulin Resistance and Type 2 Diabetes. Diabetes, 2004, 53, 842-846.	0.3	55
231	Prevalence and functionality of paucimorphic and privateMC4Rmutations in a large, unselected European British population, scanned by meltMADGE. Human Mutation, 2007, 28, 294-302.	1.1	55
232	Genetic syndromes of severe insulin resistance. Current Opinion in Genetics and Development, 2018, 50, 60-67.	1.5	55
233	Association of Genetically Enhanced Lipoprotein Lipase–Mediated Lipolysis and Low-Density Lipoprotein Cholesterol–Lowering Alleles With Risk of Coronary Disease and Type 2 Diabetes. JAMA Cardiology, 2018, 3, 957.	3.0	55
234	Dunnigan-Kobberling syndrome: an autosomal dominant form of partial lipodystrophy. QJM - Monthly Journal of the Association of Physicians, 1997, 90, 27-36.	0.2	54

#	Article	IF	CITATIONS
235	The CART gene and human obesity: mutational analysis and population genetics. Diabetes, 2000, 49, 872-875.	0.3	54
236	Formalising recall by genotype as an efficient approach to detailed phenotyping and causal inference. Nature Communications, 2018, 9, 711.	5.8	54
237	Evidence for Linkage of Stature to Chromosome 3p26 in a Large U.K. Family Data Set Ascertained for Type 2 Diabetes. American Journal of Human Genetics, 2002, 70, 543-546.	2.6	53
238	Association and Haplotype Analysis of the Insulin-Degrading Enzyme (IDE) Gene, a Strong Positional and Biological Candidate for Type 2 Diabetes Susceptibility. Diabetes, 2003, 52, 1300-1305.	0.3	52
239	Inhibition of mitochondrial function by metformin increases glucose uptake, glycolysis and GDF-15 release from intestinal cells. Scientific Reports, 2021, 11, 2529.	1.6	52
240	Melaninâ€Concentrating Hormone Receptor Mutations and Human Obesity: Functional Analysis. Obesity, 2004, 12, 743-749.	4.0	50
241	Mutations in the Amino-Terminal Region of Proopiomelanocortin (POMC) in Patients with Early-Onset Obesity Impair POMC Sorting to the Regulated Secretory Pathway. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 4494-4499.	1.8	50
242	Treatment with Recombinant Human Insulin-Like Growth Factor (rhIGF)-I/rhIGF Binding Protein-3 Complex Improves Metabolic Control in Subjects with Severe Insulin Resistance. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 2113-2122.	1.8	50
243	Rare Variant Analysis of Human and Rodent Obesity Genes in Individuals with Severe Childhood Obesity. Scientific Reports, 2017, 7, 4394.	1.6	50
244	Two Naturally Occurring Mutant Insulin Receptors Phosphorylate Insulin Receptor Substrate-1 (IRS-1) but Fail to Mediate the Biological Effects of Insulin. Journal of Biological Chemistry, 1996, 271, 7134-7140.	1.6	49
245	Differential effects of \hat{l}_{\pm} , \hat{l}_{\pm} and \hat{l}_{\pm} 2-melanocyte-stimulating hormones on hypothalamic neuronal activation and feeding in the fasted rat. Neuroscience, 2001, 108, 437-445.	1.1	49
246	Hypoglycemia due to an Insulin Binding Antibody in a Patient with an IgA-κ Myeloma. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 2013-2016.	1.8	49
247	Loss-of-function mutations in the melanocortin 4 receptor in a UK birth cohort. Nature Medicine, 2021, 27, 1088-1096.	15.2	49
248	Insulin resistance uncoupled from dyslipidemia due to C-terminal PIK3R1 mutations. JCI Insight, 2016, 1, e88766.	2.3	49
249	Impaired activation of phosphoinositide 3-kinase by insulin in fibroblasts from patients with severe insulin resistance and pseudoacromegaly. A disorder characterized by selective postreceptor insulin resistance Journal of Clinical Investigation, 1998, 101, 1111-1120.	3.9	49
250	Potentiation of Glucose Uptake in 3T3-L1 Adipocytes by PPARÂ Agonists Is Maintained in Cells Expressing a PPARÂ Dominant-Negative Mutant: Evidence for Selectivity in the Downstream Responses to PPARÂ Activation. Molecular Endocrinology, 2001, 15, 1729-1738.	3.7	49
251	A Low-Frequency Inactivating <i>AKT2</i> Variant Enriched in the Finnish Population Is Associated With Fasting Insulin Levels and Type 2 Diabetes Risk. Diabetes, 2017, 66, 2019-2032.	0.3	47
252	Role of the POZ Zinc Finger Transcription Factor FBI-1 in Human and Murine Adipogenesis. Journal of Biological Chemistry, 2004, 279, 11711-11718.	1.6	46

#	Article	IF	Citations
253	Energy Expenditure and Adaptive Responses to an Acute Hypercaloric Fat Load in Humans with Lipodystrophy. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 1446-1452.	1.8	46
254	Sequențial Regulation of Diacylglycerol Acyltransferase 2 Expression by CAAT/Enhancer-binding Protein β (C/EBPβ) and C/EBPα during Adipogenesis. Journal of Biological Chemistry, 2007, 282, 21005-21014.	1.6	46
255	Evaluating the Role of <i>LPIN1</i> Variation in Insulin Resistance, Body Weight, and Human Lipodystrophy in U.K. Populations. Diabetes, 2008, 57, 2527-2533.	0.3	46
256	Divergent effects of central melanocortin signalling on fat and sucrose preference in humans. Nature Communications, 2016, 7, 13055.	5.8	46
257	Does Physical Activity Energy Expenditure Explain the Between-Individual Variation in Plasma Leptin Concentrations after Adjusting for Differences in Body Composition?. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 3258-3263.	1.8	45
258	Large-scale studies of the association between variation at the TNF/LTA locus and susceptibility to type 2 diabetes. Diabetologia, 2005, 48, 2013-2017.	2.9	45
259	Steroid receptor coactivator-1 modulates the function of Pomc neurons and energy homeostasis. Nature Communications, 2019, 10, 1718.	5.8	45
260	ob gene mutations and human obesity. Proceedings of the Nutrition Society, 1998, 57, 471-475.	0.4	44
261	Resistin: a new link between obesity and insulin resistance?. Clinical Endocrinology, 2001, 55, 437-438.	1.2	44
262	Monogenic polycystic ovary syndrome due to a mutation in the lamin A/C gene is sensitive to thiazolidinediones but not to metformin. European Journal of Endocrinology, 2008, 159, 347-353.	1.9	44
263	A Prevalent Variant in PPP1R3A Impairs Glycogen Synthesis and Reduces Muscle Glycogen Content in Humans and Mice. PLoS Medicine, 2008, 5, e27.	3.9	44
264	Investigating the involvement of the ATF6 \hat{i} ± pathway of the unfolded protein response in adipogenesis. International Journal of Obesity, 2012, 36, 1248-1251.	1.6	43
265	Deletion of Codons 88–92 of the Melanocortin-4 Receptor Gene: A Novel Deleterious Mutation in an Obese Female. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 5841-5845.	1.8	41
266	Familial partial lipodystrophy associated with compound heterozygosity for novel mutations in the LMNA gene. Diabetologia, 2004, 47, 753-756.	2.9	41
267	Molecular Genetic Analysis of Normosmic Hypogonadotropic Hypogonadism in a Turkish Population: Identification and Detailed Functional Characterization of a Novel Mutation in the Gonadotropin-Releasing Hormone Receptor Gene. Neuroendocrinology, 2006, 84, 301-308.	1.2	41
268	Studies of the Peptide YY and Neuropeptide Y2 Receptor Genes in Relation to Human Obesity and Obesity-Related Traits. Diabetes, 2004, 53, 2461-2466.	0.3	40
269	Studies of the SIM1 gene in relation to human obesity and obesity-related traits. International Journal of Obesity, 2007, 31, 429-434.	1.6	40
270	Functional Characterization of Naturally Occurring Pathogenic Mutations in the Human Leptin Receptor. Endocrinology, 2008, 149, 6043-6052.	1.4	40

#	Article	IF	CITATIONS
271	Severe insulin resistance due to antiâ€insulin antibodies: response to plasma exchange and immunosuppressive therapy. Diabetic Medicine, 2009, 26, 79-82.	1.2	40
272	Activation of the hypothalamic–pituitary–adrenal axis by exogenous and endogenous GDF15. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3. 3	40
273	Associations of vomiting and antiemetic use in pregnancy with levels of circulating GDF15 early in the second trimester: A nested case-control study. Wellcome Open Research, 2018, 3, 123.	0.9	40
274	Contraction inhibits insulin-stimulated insulin receptor substrate-1/2-associated phosphoinositide 3-kinase activity, but not protein kinase B activation or glucose uptake, in rat muscle. Biochemical Journal, 2000, 349, 775-781.	1.7	39
275	A Dominant Negative Human Peroxisome Proliferator-Activated Receptor (PPAR) \hat{l}_{\pm} Is a Constitutive Transcriptional Corepressor and Inhibits Signaling through All PPAR Isoforms. Endocrinology, 2005, 146, 1871-1882.	1.4	39
276	Mechanistic insights into insulin resistance in the genetic era. Diabetic Medicine, 2011, 28, 1476-1486.	1.2	39
277	Analysis of naturally occurring mutations in the human lipodystrophy protein seipin reveals multiple potential pathogenic mechanisms. Diabetologia, 2013, 56, 2498-2506.	2.9	39
278	Functional Characterization of Obesity-Associated Variants Involving the \hat{l}_{\pm} and \hat{l}_{\pm} Isoforms of Human SH2B1. Endocrinology, 2014, 155, 3219-3226.	1.4	39
279	Pro-Opiomelanocortin Modulates the Thermogenic and Physical Activity Responses to High-Fat Feeding and Markedly Influences Dietary Fat Preference. Endocrinology, 2007, 148, 5331-5338.	1.4	38
280	Identification of the Global Transcriptomic Response of the Hypothalamic Arcuate Nucleus to Fasting and Leptin. Journal of Neuroendocrinology, 2010, 22, 915-925.	1.2	38
281	Exome Sequencing Identifies Genes and Gene Sets Contributing to Severe Childhood Obesity, Linking PHIP Variants to Repressed POMC Transcription. Cell Metabolism, 2020, 31, 1107-1119.e12.	7.2	38
282	Controlling the glucose factory. Nature, 2001, 413, 125-126.	13.7	36
283	The Effect of the Gly16Arg Polymorphism of thel² 2-Adrenergic Receptor Gene on Plasma Free Fatty Acid Levels Is Modulated by Physical Activity. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 5881-5887.	1.8	36
284	PGC-1?? Genotype Modifies the Association of Volitional Energy Expenditure with &OV0312O2max. Medicine and Science in Sports and Exercise, 2003, 35, 1998-2004.	0.2	36
285	<i>FTO</i> Obesity Variant and Adipocyte Browning in Humans. New England Journal of Medicine, 2016, 374, 190-193.	13.9	36
286	Lamin Expression in Human Adipose Cells in Relation to Anatomical Site and Differentiation State. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 728-734.	1.8	35
287	Melanocortin receptors weigh in. Nature Medicine, 2004, 10, 351-352.	15.2	35
288	Sequence variants in the melatonin-related receptor gene (GPR50) associate with circulating triglyceride and HDL levels. Journal of Lipid Research, 2006, 47, 761-766.	2.0	35

#	Article	IF	Citations
289	Development, factor structure and application of the Dog Obesity Risk and Appetite (DORA) questionnaire. Peerl, 2015, 3, e1278.	0.9	35
290	GDF15â€"From Biomarker to Allostatic Hormone. Cell Metabolism, 2017, 26, 807-808.	7.2	35
291	Differential Effects of Adiposity on Peroxisomal Proliferator-Activated Receptor Î ³ 1 and Î ³ 2 Messenger Ribonucleic Acid Expression in Human Adipocytes. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 4203-4207.	1.8	34
292	Natural variants of human p85α phosphoinositide 3-kinase in severe insulin resistance: a novel variant with impaired insulin-stimulated lipid kinase activity. Diabetologia, 2000, 43, 321-331.	2.9	33
293	Class II Phosphoinositide 3-Kinase Is Activated by Insulin but Not by Contraction in Skeletal Muscle. Archives of Biochemistry and Biophysics, 2001, 396, 244-248.	1.4	33
294	Hypoglycemia and Resistance to Ketoacidosis in a Subject without Functional Insulin Receptors. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 3319-3326.	1.8	33
295	Lamin A/C Polymorphisms, Type 2 Diabetes, and the Metabolic Syndrome: Case-Control and Quantitative Trait Studies. Diabetes, 2007, 56, 884-889.	0.3	33
296	Defective peroxisomal proliferators activated receptor gamma activity due to dominantâ€negative mutation synergizes with hypertension to accelerate cardiac fibrosis in mice. European Journal of Heart Failure, 2009, 11, 533-541.	2.9	32
297	Hypoinsulinaemic, hypoketotic hypoglycaemia due to mosaic genetic activation of PI3-kinase. European Journal of Endocrinology, 2017, 177, 175-186.	1.9	32
298	Differential Signaling to Glycogen Synthesis by the Intracellular Domain of the Insulin versus the Insulin-like Growth Factor-1 Receptor. Journal of Biological Chemistry, 1997, 272, 24325-24332.	1.6	31
299	Molecular scanning of the insulin receptor substrate 1 gene in subjects with severe insulin resistance: detection and functional analysis of a naturally occurring mutation in a YMXM motif. Diabetes, 1998, 47, 837-839.	0.3	31
300	Sequence data and association statistics from 12,940 type 2 diabetes cases and controls. Scientific Data, 2017, 4, 170179.	2.4	31
301	Contributions of Function-Altering Variants in Genes Implicated in Pubertal Timing and Body Mass for Self-Limited Delayed Puberty. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 649-659.	1.8	31
302	Severe Hypo-Â-Lipoproteinemia During Treatment With Rosiglitazone. Diabetes Care, 2004, 27, 2577-2580.	4.3	30
303	A Pharmacogenetic Approach to the Treatment of Patients With <i>PPARG</i> Mutations. Diabetes, 2018, 67, 1086-1092.	0.3	30
304	Low-frequency variation in TP53 has large effects on head circumference and intracranial volume. Nature Communications, 2019, 10, 357.	5.8	30
305	Peripheral administration of the N-terminal pro-opiomelanocortin fragment 1–28 to Pomcâ⁻'/â⁻' mice reduces food intake and weight but does not affect adrenal growth or corticosterone production. Journal of Endocrinology, 2006, 190, 515-525.	1.2	29
306	A Clinical Approach to Severe Insulin Resistance. , 2007, 11, 122-132.		29

#	Article	IF	Citations
307	Adiponectin receptor genes: mutation screening in syndromes of insulin resistance and association studies for type 2 diabetes and metabolic traits in UK populations. Diabetologia, 2007, 50, 555-562.	2.9	29
308	Leptin: a novel therapeutic role in lipodystrophy. Journal of Clinical Investigation, 2002, 109, 1285-1286.	3.9	29
309	Molecular scanning of the insulin receptor gene in syndromes of insulin resistance. Diabetes, 1994, 43, 357-368.	0.3	29
310	Rapid and simultaneous detection of multiple mutations by pooled and multiplex single nucleotide primer extension: application to the study of insulin-responsive glucose transporter and insulin receptor mutations in non-insulindependent diabetes. Human Molecular Genetics, 1992, 1, 391-395.	1.4	28
311	Functional activation of mutant human insulin receptor by monoclonal antibody. Lancet, The, 1996, 347, 1586-1590.	6.3	28
312	Association of Polymorphisms in GPR10, the Gene Encoding the Prolactin-Releasing Peptide Receptor With Blood Pressure, but not Obesity, in a U.K. Caucasian Population. Diabetes, 2003, 52, 1296-1299.	0.3	28
313	Genetic variation in the corticotrophin-releasing factor receptors: identification of single-nucleotide polymorphisms and association studies with obesity in UK Caucasians. International Journal of Obesity, 2004, 28, 442-446.	1.6	28
314	Human obesity and insulin resistance: lessons from experiments of Nature. Biochemical Society Transactions, 2007, 35, 33-36.	1.6	28
315	The Gly482Ser genotype at the <i>PPARGC1A</i> gene and elevated blood pressure: a meta-analysis involving 13,949 individuals. Journal of Applied Physiology, 2008, 105, 1352-1358.	1.2	28
316	Metabolic insights from extreme human insulin resistance phenotypes. Best Practice and Research in Clinical Endocrinology and Metabolism, 2012, 26, 145-157.	2.2	28
317	The Effect of the Gly16Arg Polymorphism of the Â2-Adrenergic Receptor Gene on Plasma Free Fatty Acid Levels Is Modulated by Physical Activity. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 5881-5887.	1.8	28
318	Depot-related and thiazolidinedione-responsive expression of uncoupling protein 2 (UCP2) in human adipocytes. International Journal of Obesity, 2000, 24, 585-592.	1.6	27
319	Association Between Physical Activity and Blood Pressure Is Modified by Variants in the G-Protein Coupled Receptor 10. Hypertension, 2004, 43, 224-228.	1.3	27
320	Analysis of the contribution to type 2 diabetes susceptibility of sequence variation in the gene encoding stearoyl-CoA desaturase, a key regulator of lipid and carbohydrate metabolism. Diabetologia, 2004, 47, 2168-2175.	2.9	27
321	Kinetic analysis of FTO (fat mass and obesity-associated) reveals that it is unlikely to function as a sensor for 2-oxoglutarate. Biochemical Journal, 2012, 444, 183-187.	1.7	27
322	Fatty Acid Metabolism in Patients with PPARÎ ³ Mutations. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 4462-4470.	1.8	26
323	Mitochondrial Oxidative Phosphorylation Is Impaired in Patients with Congenital Lipodystrophy. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E438-E442.	1.8	26
324	Successful treatment of Type B insulin resistance in a patient with otherwise quiescent systemic lupus erythematosus. Diabetic Medicine, 2005, 22, 814-815.	1.2	25

#	Article	IF	CITATIONS
325	Genetic Variance in the Spinocerebellar Ataxia Type 2 (ATXN2) Gene in Children with Severe Early Onset Obesity. PLoS ONE, 2009, 4, e8280.	1.1	25
326	Thiazolidinedione exposure increases the expression of uncoupling protein 1 in cultured human preadipocytes. Diabetes, 1998, 47, 138-141.	0.3	25
327	Tumor Necrosis Factor-Induced Cytotoxicity is Not Related to Rates of Mitochondrial Morphological Abnormalities or Autophagy-Changes that can be Mediated by TNFR-I or TNFR-II. Bioscience Reports, 1998, 18, 329-340.	1.1	24
328	Triple H Syndrome: A Novel Autoimmune Endocrinopathy Characterized by Dysfunction of the Hippocampus, Hair Follicle, and Hypothalamic-Pituitary-Adrenal Axis. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 2644-2648.	1.8	24
329	Hypercalcaemia associated with granulomatous lymphadenitis and elevated 1,25 dihydroxyvitamin D concentration in a dog. Journal of Small Animal Practice, 2006, 47, 207-212.	0.5	24
330	Significant Linkage of BMI to Chromosome 10p in the U.K. Population and Evaluation of GAD2 as a Positional Candidate. Diabetes, 2006, 55, 1884-1889.	0.3	24
331	Orexin Expression is Regulated by ?-Melanocyte-Stimulating Hormone. Journal of Neuroendocrinology, 2007, 19, 703-707.	1.2	24
332	The metabolic syndrome- associated small G protein ARL15 plays a role in adipocyte differentiation and adiponectin secretion. Scientific Reports, 2017, 7, 17593.	1.6	24
333	The α-isoform of class II phosphoinositide 3-kinase is more effectively activated by insulin receptors than IGF receptors, and activation requires receptor NPEY motifs. FEBS Letters, 1999, 460, 423-426.	1.3	23
334	Insights into obesity and insulin resistance from the study of extreme human phenotypes. European Journal of Endocrinology, 2002, 147, 435-441.	1.9	23
335	Variation in the eNOS Gene Modifies the Association Between Total Energy Expenditure and Glucose Intolerance. Diabetes, 2005, 54, 2795-2801.	0.3	23
336	PPARGC1A coding variation may initiate impaired NEFA clearance during glucose challenge. Diabetologia, 2007, 50, 569-573.	2.9	23
337	Mechanistic insights revealed by lipid profiling in monogenic insulin resistance syndromes. Genome Medicine, 2015, 7, 63.	3.6	23
338	Mutational analysis of the serotonin receptor 5HT2c in severe early-onset human obesity. Canadian Journal of Physiology and Pharmacology, 2004, 82, 426-429.	0.7	22
339	Polymorphisms in the gene encoding sterol regulatory element-binding factor-1c are associated with type 2 diabetes. Diabetologia, 2006, 49, 2642-2648.	2.9	22
340	The NR4A family of orphan nuclear receptors are not required for adipogenesis. International Journal of Obesity, 2008, 32, 388-392.	1.6	22
341	Loss of Agouti-Related Peptide Does Not Significantly Impact the Phenotype of Murine POMC Deficiency. Endocrinology, 2011, 152, 1819-1828.	1.4	22
342	FTO is necessary for the induction of leptin resistance by high-fat feeding. Molecular Metabolism, 2015, 4, 287-298.	3.0	22

#	Article	IF	Citations
343	Circulating levels of GDF15 in patients with myalgic encephalomyelitis/chronic fatigue syndrome. Journal of Translational Medicine, 2019, 17, 409.	1.8	22
344	Trappc9 deficiency causes parent-of-origin dependent microcephaly and obesity. PLoS Genetics, 2020, 16, e1008916.	1.5	22
345	Comparison of anti-apoptotic signalling by the insulin receptor and IGF-I receptor in preadipocytes and adipocytes. Cellular Signalling, 2001, 13, 279-285.	1.7	21
346	Quantitative mass spectrometry for human melanocortin peptides in \hat{A} vitro and in \hat{A} vivo suggests prominent roles for \hat{I}^2 -MSH and desacetyl \hat{I}_\pm -MSH in energy homeostasis. Molecular Metabolism, 2018, 17, 82-97.	3.0	21
347	Functional characterization of a novel insulin receptor mutation contributing to Rabson?Mendenhall syndrome. Clinical Endocrinology, 2006, 66, 060912083525001-???.	1.2	20
348	Peripheral mechanisms contributing to the glucocorticoid hypersensitivity in proopiomelanocortin null mice treated with corticosterone. Journal of Endocrinology, 2007, 194, 161-170.	1.2	20
349	Truncation of POC1A associated with short stature and extreme insulin resistance. Journal of Molecular Endocrinology, 2015, 55, 147-158.	1.1	20
350	Leptin-Mediated Changes in the Human Metabolome. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 2541-2552.	1.8	20
351	Efficacy of Metreleptin for Weight Loss in Overweight and Obese Adults with Low Leptin Levels. Diabetes, 2018, 67, .	0.3	19
352	Leptin therapy in lipodystrophy. Diabetologia, 2010, 53, 7-9.	2.9	18
353	Shedding pounds after going under the knife: Guts over glory—why diets fail. Nature Medicine, 2012, 18, 666-667.	15.2	18
354	Obesity-Associated Melanocortin-4 Receptor Mutations Are Associated With Changes in the Brain Response to Food Cues. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E2101-E2106.	1.8	18
355	Insulin Receptor and the Kidney: Nephrocalcinosis in Patients with Recessive INSR Mutations. Nephron Physiology, 2015, 128, 55-61.	1.5	18
356	No Evidence for Linkage at Candidate Type 2 Diabetes Susceptibility Loci on Chromosomes 12 and 20 in United Kingdom Caucasians. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 853-857.	1.8	17
357	Adipose depot-specific expression of cIAP2 in human preadipocytes and modulation of expression by serum factors and TNFî±. International Journal of Obesity, 2001, 25, 1027-1033.	1.6	17
358	Genetic Variants and Common Diseases â€" Better Late Than Never. New England Journal of Medicine, 2006, 355, 306-308.	13.9	17
359	Lamin Expression in Human Adipose Cells in Relation to Anatomical Site and Differentiation State., 0, .		17
360	Steroid hormones and adipose tissue. European Journal of Clinical Investigation, 1996, 26, 259-261.	1.7	16

#	Article	IF	Citations
361	Uncoupling protein 2: Adiposity angel and diabetes devil?. Nature Medicine, 2001, 7, 770-772.	15.2	16
362	PARL Leu262Val is not associated with fasting insulin levels in UK populations. Diabetologia, 2006, 49, 2649-2652.	2.9	16
363	Roux-en-Y Gastric Bypass Surgery in the Management of Familial Partial Lipodystrophy Type 1. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 3616-3620.	1.8	16
364	European paediatric non-alcoholic fatty liver disease registry (EU-PNAFLD): Design and rationale. Contemporary Clinical Trials, 2018, 75, 67-71.	0.8	16
365	Ovarian Hyperandrogenism and Response to Gonadotropin-releasing Hormone Analogues in Primary Severe Insulin Resistance. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 2367-2383.	1.8	16
366	Proopiomelanocortin Products and Human Early-Onset Obesity. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 819-820.	1.8	15
367	Peptide YY3–36 and Satiety: Clarity or Confusion?. Endocrinology, 2004, 145, 2582-2584.	1.4	15
368	Physical activity energy expenditure may mediate the relationship between plasma leptin levels and worsening insulin resistance independently of adiposity. Journal of Applied Physiology, 2007, 102, 1921-1926.	1.2	15
369	SnapShot: The Hormonal Control of Food Intake. Cell, 2008, 135, 572.e1-572.e2.	13.5	15
370	Disruption of the homeodomain transcription factor orthopedia homeobox (Otp) is associated with obesity and anxiety. Molecular Metabolism, 2017, 6, 1419-1428.	3.0	15
371	Constitutive Activation of AKT2 in Humans Leads to Hypoglycemia Without Fatty Liver or Metabolic Dyslipidemia. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 2914-2921.	1.8	15
372	Naturally occurring amino acid substitutions at Arg1174 in the human insulin receptor result in differential effects on receptor biosynthesis and hybrid formation, leading to discordant clinical phenotypes Diabetes, 2000, 49, 1264-1268.	0.3	14
373	Deletion of V335 from the L2 Domain of the Insulin Receptor Results in a Conformationally Abnormal Receptor That Is Unable to Bind Insulin and Causes Donohue's Syndrome in a Human Subject. Endocrinology, 2003, 144, 631-637.	1.4	14
374	Truncation of Pik3r1 causes severe insulin resistance uncoupled from obesity and dyslipidaemia by increased energy expenditure. Molecular Metabolism, 2020, 40, 101020.	3.0	14
375	Expression of the putative inhibitor of the insulin receptor tyrosine kinase PCâ€1 in dermal fibroblasts from patients with syndromes of severe insulin resistance. Clinical Endocrinology, 1997, 47, 65-70.	1.2	13
376	Harveian Oration 2016: Some observations on the causes and consequences of obesity. Clinical Medicine, 2016, 16, 551-564.	0.8	13
377	Genetic variants of insulin receptor substrate-1 (IRS-1) in syndromes of severe insulin resistance. Functional analysis of Ala513Pro and Gly1158Glu IRS-1. Diabetic Medicine, 2002, 19, 804-809.	1.2	12
378	Analysis of TBC1D4 in patients with severe insulin resistance. Diabetologia, 2010, 53, 1239-1242.	2.9	12

#	Article	IF	Citations
379	Relationship between Changes in Plasma Adiponectin Concentration and Insulin Sensitivity after Niacin Therapy. CardioRenal Medicine, 2012, 2, 211-217.	0.7	12
380	Metabolic Precision Medicines: Curing POMC Deficiency. Cell Metabolism, 2016, 24, 194-195.	7.2	12
381	GDF15 Is Elevated in Conditions of Glucocorticoid Deficiency and Is Modulated by Glucocorticoid Replacement. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 1427-1434.	1.8	12
382	Identification of Rare Loss-of-Function Genetic Variation Regulating Body Fat Distribution. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 1065-1077.	1.8	12
383	Studies of the neuromedin U-2 receptor gene in human obesity: evidence for the existence of two ancestral forms of the receptor. Journal of Endocrinology, 2004, 183, 115-120.	1.2	11
384	Modernising Medical Careers, Medical Training Application Service, and the Postgraduate Medical Education and Training Board: time for the emperors to don their clothes. Lancet, The, 2007, 369, 967-968.	6.3	11
385	Early Diagnosis of Werner's Syndrome Using Exome-Wide Sequencing in a Single, Atypical Patient. Frontiers in Endocrinology, 2011, 2, 8.	1.5	11
386	Uncovering the biology of FTO. Molecular Metabolism, 2012, 1, 32-36.	3.0	11
387	20 YEARS OF LEPTIN: What we know and what the future holds. Journal of Endocrinology, 2014, 223, E1-E3.	1.2	11
388	AMPK is required for exercise to enhance insulin sensitivity in skeletal muscles. Molecular Metabolism, 2017, 6, 315-316.	3.0	11
389	The Imprinted Gene Peg3 Is Not Essential for Tumor Necrosis Factor α Signaling. Laboratory Investigation, 2000, 80, 1509-1511.	1.7	10
390	Is leptin an important physiological regulator of CRP?. Nature Medicine, 2007, 13, 16-17.	15.2	10
391	Identification and Characterisation of a Novel Pathogenic Mutation in the Human Lipodystrophy Gene AGPAT2. JIMD Reports, 2012, 9, 73-80.	0.7	10
392	Knockdown of diacylglycerol kinase delta inhibits adipocyte differentiation and alters lipid synthesis. Obesity, 2013, 21, 1823-1829.	1.5	10
393	Impaired prohormone processing: a grand unified theory for features of Prader-Willi syndrome?. Journal of Clinical Investigation, 2016, 127, 98-99.	3.9	10
394	Diabetes in midlife: Planting genetic time bombs. Nature Medicine, 1997, 3, 1080-1081.	15.2	9
395	Hypoketotic Hypofattyacidaemic Hypoinsulinaemic Hypoglycaemia in a Child with Hemihypertrophy? A New Syndrome. Hormone Research in Paediatrics, 2004, 61, 222-227.	0.8	9
396	Phenotypic characterization of Adig null mice suggests roles for adipogenin in the regulation of fat mass accrual and leptin secretion. Cell Reports, 2021, 34, 108810.	2.9	9

#	Article	IF	Citations
397	Obesity therapeutics: The end of the beginning. Cell Metabolism, 2021, 33, 705-706.	7.2	9
398	Physical Activity and Insulin Resistance. , 2005, , 317-400.		8
399	IRS2 variants and syndromes of severe insulin resistance. Diabetologia, 2009, 52, 1208-1211.	2.9	8
400	Syndromes of Severe Insulin Resistance and/or Lipodystrophy. , 2010, , 39-52.		8
401	Founder effect in the Horn of Africa for an insulin receptor mutation that may impair receptor recycling. Diabetologia, 2011, 54, 1057-1065.	2.9	8
402	Adipogenesis at a glance. Journal of Cell Science, 2011, 124, 3726-3726.	1.2	8
403	Characterisation of proguanylin expressing cells in the intestine – evidence for constitutive luminal secretion. Scientific Reports, 2019, 9, 15574.	1.6	8
404	The Common H202D Variant in GDF-15 Does Not Affect Its Bioactivity but Can Significantly Interfere with Measurement of Its Circulating Levels. journal of applied laboratory medicine, The, 2022, 7, 1388-1400.	0.6	8
405	The metabolic syndrome: all in the mind?. Diabetic Medicine, 1999, 16, 355-357.	1.2	7
406	Examining the Candidacy of Ghrelin as a Gene Responsible for Variation in Adult Stature in a United Kingdom Population with Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 2201-2204.	1.8	7
407	Human Obesity and Insulin Resistance: Lessons from Experiments of Nature. Novartis Foundation Symposium, 0, , 13-23.	1.2	7
408	Heterogeneity of glucagonomas due to differential processing of proglucagon-derived peptides. Endocrinology, Diabetes and Metabolism Case Reports, 2015, 2015, 150105.	0.2	7
409	Colchicine—an old dog with new tricks. Nature Metabolism, 2021, 3, 451-452.	5.1	6
410	Epidemiological evidence against a role for C-reactive protein causing leptin resistance. European Journal of Endocrinology, 2013, 168, 101-106.	1.9	5
411	Syndromes of Severe Insulin Resistance and/or Lipodystrophy. , 2016, , 307-324.		5
412	Murine neuronatin deficiency is associated with a hypervariable food intake and bimodal obesity. Scientific Reports, 2021, 11, 17571.	1.6	5
413	Genetic Obesity Syndromes. , 2014, , 23-32.		5
414	Homozygous mutation in the insulin receptor. Clinical Endocrinology, 1996, 45, 237-238.	1.2	4

#	Article	IF	CITATIONS
415	Is the defect in pro-hormone processing in Type 2 diabetes mellitus restricted to the \hat{l}^2 cell?. Diabetic Medicine, 2001, 18, 17-21.	1.2	4
416	The coding sequence of POMC and obesity and appetite in Labrador retriever dogs. Lancet, The, 2014, 383, S86.	6.3	4
417	The wasting hormone GDF15 frees up fat to fight infection. Nature Metabolism, 2019, 1, 935-936.	5.1	4
418	Finding genes that control body weight. Science, 2021, 373, 30-31.	6.0	4
419	The McKittrick–Wheelock syndrome: a rare cause of curable diabetes. Endocrinology, Diabetes and Metabolism Case Reports, 2016, 2016, 160013.	0.2	4
420	Excessive secretion of insulin precursors characterizes and predicts gestational diabetes. Diabetes, 1995, 44, 911-915.	0.3	4
421	Gestational Diabetes Mellitus Is Associated With an Increase in the Total Concentration of Amylin Molecules. Diabetes Care, 1998, 21, 668-669.	4.3	3
422	Genetics of the Metabolic Syndrome. , 2005, , 401-450.		3
423	Medical training in the UK: sleepwalking to disaster. Lancet, The, 2007, 369, 1673-1675.	6.3	3
424	The islet's bridesmaid becomes the bride: Proglucagon-derived peptides deliver transformative therapies. Cell, 2021, 184, 1945-1948.	13.5	3
425	"Treasure Your Exceptionsâ€â€"Studying Human Extreme Phenotypes to Illuminate Metabolic Health and Disease: The 2019 Banting Medal for Scientific Achievement Lecture. Diabetes, 2021, 70, 29-38.	0.3	3
426	Insulin-Mediated Regulation of Glucose Metabolism. , 2005, , 63-85.		2
427	Genetically Modified Mouse Models of Insulin Resistance. , 2005, , 133-153.		2
428	Severe Hypoinsulinaemic Hypoglycaemia in a Premature Infant Associated with Poor Weight Gain and Reduced Adipose Tissue. Hormone Research in Paediatrics, 2007, 68, 91-98.	0.8	2
429	An Appreciation of Robert Turner. Diabetes, 2008, 57, 2918-2921.	0.3	2
430	Abdominal subcutaneous adipose tissue morphology in a patient with a dominant-negative mutation (P467L) in the nuclear receptor peroxisome proliferator-activated receptor-gamma (PPARG) gene. Nutrition, Metabolism and Cardiovascular Diseases, 2010, 20, e11-e12.	1.1	2
431	Loss of <i>NPC1</i> function in a patient with a coâ€inherited novel insulin receptor mutation does not grossly modify the severity of the associated insulin resistance. Journal of Inherited Metabolic Disease, 2010, 33, 227-232.	1.7	2
432	Assessment of Acute and Chronic Pharmacological Effects on Energy Expenditure and Macronutrient Oxidation in Humans: Responses to Ephedrine. Journal of Obesity, 2011, 2011, 1-8.	1.1	2

#	Article	IF	Citations
433	Human obesity and insulin resistance: Lessons from human genetics. Clinical Biochemistry, 2011, 44, 451.	0.8	2
434	How to Stop the Obesity Epidemic?. Cell, 2015, 161, 173-174.	13.5	2
435	A multicomponent screen for feeding behaviour and nutritional status in Drosophila to interrogate mammalian appetite-related genes. Molecular Metabolism, 2021, 43, 101127.	3.0	2
436	Genetic Evaluation of Obese Patients. , 2008, , 45-54.		2
437	Human obesity and insulin resistance: lessons from experiments of nature. Novartis Foundation Symposium, 2007, 286, 13-20; discussion 20-3, 162-3, 196-203.	1.2	2
438	Glucokinase and nonâ€insulinâ€dependent diabetes. Clinical Endocrinology, 1993, 39, 17-19.	1.2	1
439	Adipokines and Insulin Resistance. , 2005, , 269-295.		1
440	Insulin Resistance in Glucose Disposal and Production in Man with Specific Reference to Metabolic Syndrome and Type 2 Diabetes., 2005,, 155-178.		1
441	The Effect of Insulin on Protein Metabolism. , 2005, , 105-132.		1
442	Relationship between Fat Distribution and Insulin Resistance. , 2005, , 207-235.		1
443	Insulin Resistance and Dyslipidaemia. , 2005, , 451-466.		1
444	Translating metabolic biochemistry into the clinic: an interview with Steve O'Rahilly. DMM Disease Models and Mechanisms, 2011, 4, 141-144.	1.2	1
445	Genetic Syndromes Associated with Obesity. , 2016, , 491-497.e2.		1
446	PSY11 - REAL-WORLD EXPERIENCE OF GENERALIZED LIPODYSTROPHY PATIENTS ENROLLED IN THE METRELEPTIN EARLY ACCESS PROGRAM: INITIAL RESULTS. Value in Health, 2018, 21, S437.	0.1	1
447	A classification of videoconferencing related illness: the Zoomnotic diseases. QJM - Monthly Journal of the Association of Physicians, 2021, 114, 159-162.	0.2	1
448	Reply to G Taubes, MI Friedman, and V Torres-Carot et al. American Journal of Clinical Nutrition, 2022, 116, 614-615.	2.2	1
449	Molecular aspects of non-insulin-dependent diabetes. Eye, 1993, 7, 214-217.	1.1	0
450	Therapeutic Strategies for Insulin Resistance. , 2005, , 535-560.		0

#	Article	IF	CITATIONS
451	Insulin Resistance and Polycystic Ovary Syndrome. , 2005, , 485-509.		О
452	The Insulin Receptor and Downstream Signalling. , 2005, , 1-62.		0
453	Dietary Factors and Insulin Resistance. , 2005, , 297-316.		O
454	Insulin Action on Lipid Metabolism. , 2005, , 87-103.		0
455	Insulin Resistance, Hypertension and Endothelial Dysfunction., 2005,, 467-483.		O
456	Syndromes of Severe Insulin Resistance (SSIRs)., 2005,, 511-533.		0
457	Drug Therapy for Insulin Resistance - a Look at the Future. , 2005, , 561-585.		0
458	PPARÎ ³ and Glucose Homeostasis. , 2005, , 237-267.		0
459	Central Regulation of Peripheral Glucose Metabolism. , 2005, , 179-206.		O
460	Genetics of chronic disease: obesity. , 0, , 328-343.		0
461	Commentary on the Classification and Diagnosis of Diabetes. , 0, , 25-28.		0
462	A case of type B insulin resistance presenting at a district general hospital. Practical Diabetes, 2020, 37, 93-95.	0.1	0
463	Constitutional Thinness: tALKing the tALK or wALKing the wALK?. Cell Metabolism, 2020, 32, 8-10.	7.2	О
464	Genetic Syndromes Associated with Obesity. , 2010, , 566-574.		0
465	Human SH2B1 mutations are associated with maladaptive behaviors and obesity. Journal of Clinical Investigation, 2013, 123, 526-526.	3.9	0
466	Melanocortin 2 receptor accessory protein 2 (Mrap2) regulates hypothalamic melanocortin-4-receptor trafficking in vivo. Endocrine Abstracts, 0, , .	0.0	0